Do you know which factors influence your risk of developing atrial fibrillation?

Atrial fibrillation (AF) can increase your risk of developing blood clots, stroke, heart failure and other complications.
Get ahead of the disease. If you know your risk, you can make proactive changes to prevent AF from occurring.
Manage your risk before you develop AF, or any associated diseases.
geneType™ for Atrial Fibrillation is appropriate for:
geneType™ reports help you and your health provider translate your personal clinical, family and genetic data into an actionable preventable health plan.
Key features of the report:
Risk reducing options exist for you.
To order online through our patient portal, follow these four simple steps to be connected with a third-party telehealth provider.
Register for your geneType™ test using our portal.
Depending on the test, you may require access to your medical records (ex. lipid panel or breast density results).
Payment will be collected at time of registration.
Your clinical information will be reviewed by our 3rd party telehealth partner, DNA Visit.
If you qualify for testing, a kit will be shipped to your address on file.
If you do not qualify for testing, you will receive a refund.
Complete buccal sample collection as instructed and return in pre-paid envelope.
Do not eat, drink, smoke, vape or chew gum within 30 minutes of collection.
When your results are ready, you will have the chance to speak with your DNA Visit healthcare provider.
All at-risk patients will be required to speak with the provider prior to results-release.
If your question is not shown here, please Contact us directly.
No. At this time geneType™ is a self-pay test. However, you may use FSA/HSA to pay for the test.
It is not possible to incorporate all potential risk factors for atrial fibrillation into a single risk prediction model. However, geneType™ incorporates the most impactful factors. Test results should be interpreted by a health provider in the context of your clinical and family history.
Yes.
While there are other companies out there that provide random lists of genetic markers that are associated with atrial fibrillation, there are no checks and balances associated with the results they provide. Most of the markers they pull from peer-reviewed publications without cross validating the markers. And more importantly, geneType™ goes through rigorous statistical validation of the genetic component prior to integrating it into the full model. The fully integrated geneType™ model is then validated separately.
No. Even though AF may present differently in men and women, there are currently no specific risk factors that differ between the two sexes. A woman’s age is incorporated into the model and indirectly accounts for post-menopausal changes associated with increased risk of developing AF. Please make sure you discuss all risk factors with your healthcare providers, including ones that are not in the geneType™ test.
*Patient eligibility dependent on personal medical history, age and sex
The Multi-Risk suite of tests is for adults 40-85 years of age. At maximum, a woman would be eligible for eight diseases in the panel; a man would be eligible for seven. Starting at age 30, a patient may qualify for geneType’s™ cancer risk assessments only.
Accredited For Compliance With NPAAC Standards And ISO 15189